Omnia Medical Launches FDA-Cleared PsiF DNA System, Advancing Minimally Invasive Sacroiliac Joint Fusion
Published: 22 Jan 2026
Author: Precedence Research
Omnia Medical is a rapidly expanding medical technology developer dedicated to innovative solutions for spine and interventional pain physicians. The company announced the full commercial launch of its FDA-cleared PsiF DNA Sacroiliac Joint Stabilization System.
Its launch is a significant milestone for the company since it was engaged in the development of the product. But upon its launch, it would be on the path of achieving the objective of addressing the unmet needs of patients with sacroiliac (SI) joint disorders. The PsiF DNA System was designed to fit the minimally invasive posterior SI joint fusion and is expected to provide mechanical stability as well as biological support to the long-term joint fusion.
Omnia has also incorporated new surgical guidance in the PsiF DNA platform with the PsiF Guard. This is an original technology that has been developed in partnership with the partnership of SpineGuard. PsiF Guard is an intraoperative feedback device that displays real-time feedback to the surgeons to confirm the proper placement of implants and increase the confidence of the procedure. Furthermore, the introduction of PsiF DNA is an indication of the larger plan of Omnia Medical to provide physician-originated technologies to make the complicated procedures easier without reducing clinical rigor.
Executives Statements
“The FDA clearance and commercial launch of PsiF DNA represent important milestones for Omnia Medical,” said Abigail Mann, Project Manager, SI Technologies. “They reflect our commitment to delivering physician-driven technologies that support procedural consistency while addressing the complexity of SI joint pathology. The feedback we received during the early launch phase was invaluable in shaping a system that meets real clinical demands.”
Commenting on the system’s design philosophy, Troy Schifano, Chief Executive Officer of Omnia Medical, emphasized the importance of combining biology with biomechanics. “The double-helix design was engineered to work in harmony with native anatomy,” he said. “By utilizing autograft bone from both sides of the joint, PsiF DNA supports the biological environment needed for fusion while maintaining procedural efficiency. Our goal has always been to deliver solutions that make sense clinically and practically for physicians.”